IMA203CD8

IMA203CD8 · Immatics US, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMA203CD8, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors [Phase 1, Phase 2]

See pricing